Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach
|
|
|
- Gary Patterson
- 10 years ago
- Views:
Transcription
1 Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach
2 Publishing Team Erik Tanck (production manager/designer) Joshua Weikersheimer (publisher) Copyright 2006 by the American Society for Clinical Pathology. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher. printed in Singapore ii
3 Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach M. Nadji, MD, M. Nassiri, MD, and A.R. Morales, MD Department of Pathology University of Miami Jackson Memorial Hospital and Sylvester Comprehensive Cancer Center iii
4 Preface Acknowledgments Introduction TABLE OF CONTENTS Differential Diagnosis-Based Panels 1 I. Undifferentiated Neoplasms 2 A. Large Cell 2 1. Large Cell Carcinoma vs Malignant Melanoma 2 2. Large Cell Carcinoma vs Malignant Large Cell Lymphoma 6 3. Large Cell Carcinoma vs Seminoma Malignant Melanoma vs Malignant Large Cell Lymphoma Malignant Melanoma vs Seminoma Malignant Large Cell Lymphoma vs Seminoma 16 B. Small Cell Small Cell Carcinoma vs Ewing/PNET Small Cell Carcinoma vs Rhabdomyosarcoma Rhabdomyosarcoma vs Ewing/PNET 26 C. Spindle Cell Spindle Cell Carcinoma vs Spindle Cell Melanoma Spindle Cell Carcinoma vs Spindle Cell Sarcoma 36 II. Specific Differential Diagnoses 40 A. Soft Tissue Synovial Sarcoma vs Spindle Cell Carcinoma Neurogenic Sarcoma vs Leiomyosarcoma Angiosarcoma vs Lymphangiosarcoma Neurogenic Sarcoma vs Spindle Cell Melanoma Chordoma vs Chondrosarcoma Epithelioid Angiosarcoma vs Poorly Differentiated Carcinoma 52 B. Gastrointestinal Tract Gastrointestinal Stromal Tumor vs Leiomyosarcoma Epithelioid Gastrointestinal Stromal Tumor vs Metastatic Carcinoma Gastrointestinal Tract Lymphoma vs Poorly Differentiated Carcinoma Gastrointestinal Tract Carcinoid vs Gastrointestinal Tract Carcinoma Colonic Adenocarcinoma vs Metastatic Ovarian Carcinoma Goblet Cell Carcinoid vs Adenocarcinoma of Appendix Signet Ring Cell Carcinoma vs Metastatic Lobular Carcinoma of Breast 74 viii ix x iv
5 C. Pancreas Ductal Adenocarcinoma vs Acinic Cell Carcinoma Islet Cell Tumor vs Acinic Cell Carcinoma Islet Cell Tumor vs Solid and Papillary Tumor 82 D. Liver Hepatocellular Carcinoma vs Cholangiocarcinoma Hepatocellular Carcinoma vs Metastatic Adenocarcinoma Hepatocellular Carcinoma vs Metastatic Colonic Adenocarcinoma Cholangiocarcinoma vs Metastatic Colonic Adenocarcinoma Hepatocellular Carcinoma vs Renal Cell Carcinoma Hepatocellular Carcinoma vs Adrenocortical Carcinoma Metastatic Tumors in the Liver 100 a. Metastatic Adenocarcinoma of Lung 101 b. Metastatic Small Cell Carcinoma of Lung 103 c. Metastatic Prostatic Carcinoma 105 d. Metastatic Gastrointestinal Stromal Tumor 107 e. Metastatic Malignant Melanoma 109 E. Kidney Renal Cell Carcinoma vs Urothelial Carcinoma Renal Cell Carcinoma vs Metastatic Lung Carcinoma Renal Cell Carcinoma vs Adrenocortical Tumor Angiomyolipoma vs Sarcomatoid Renal Carcinoma 120 F. Adrenal Adrenocortical Tumor vs Pheochromocytoma Adrenocortical Tumor vs Metastatic Carcinoma Pheochromocytoma vs Metastatic Carcinoma 128 G. Head & Neck Undifferentiated Nasopharyngeal Carcinoma vs Squamous Cell Carcinoma Benign Lymphoepithelial Lesion vs Malignant Lymphoma Olfactory Neuroblastoma vs Small Cell Carcinoma 136 H. Thyroid Thyroid Follicular Carcinoma vs Thyroid Medullary Carcinoma Thyroid Follicular Neoplasm vs Intrathyroid Parathyroid Adenoma Thyroid Clear Cell Carcinoma vs Metastatic Renal Cell Carcinoma 144 v
6 I. Lung Small Cell Lung Carcinoma vs Basaloid Squamous Cell Carcinoma Adenocarcinoma of Lung vs Metastatic Colonic Carcinoma Adenocarcinoma of Lung vs Metastatic Renal Cell Carcinoma Adenocarcinoma of Lung vs Metastatic Breast Carcinoma Small Cell Lung Carcinoma vs Lymphocytic Infiltrate Ewing/PNET in Lung vs Small Cell Carcinoma Langerhans Cell Histiocytosis vs Nonspecific Histiocytic Infiltrate 168 J. Pleura Malignant Mesothelioma vs Adenocarcinoma of Lung Desmoplastic Mesothelioma vs Solitary Fibrous Tumor Sarcomatoid Mesothelioma vs Sarcoma of Pleura Biphasic Mesothelioma vs Synovial Sarcoma Reactive Mesothelium vs Adenocarcinoma of Lung 182 K. Mediastinum Thymoma vs Lymphoma Thymoma vs Hodgkin Lymphoma 190 L. Abdomen Cystic Mesothelioma vs Lymphangioma Peritoneal Mesothelioma vs Ovarian Carcinoma Desmoplastic Small Cell vs Other Small Cell Tumors Adenomatoid Tumor vs Hemangioma Wilms Tumor vs Neuroblastoma 202 M. Female Genital Tract Uterine Leiomyosarcoma vs Endometrial Stromal Sarcoma Adenocarcinoma of Uterine Cervix vs Benign Glandular Hyperplasia Adenocarcinoma of Uterine Cervix vs Adenocarcinoma of Endometrium Hydatidiform Mole vs Hydropic Abortion Ovarian Epithelial Tumor vs Sex Cord Stromal Tumor Ovarian Carcinoma vs Metastatic Colonic Carcinoma 226 N. Breast Lobular Carcinoma of Breast vs Ductal Carcinoma of Breast Ductal Adenosis of Breast vs Tubular Carcinoma of Breast Metaplastic Carcinoma of Breast vs Ductal Carcinoma of Breast Medullary Carcinoma of Breast vs Ductal Carcinoma of Breast 238 vi
7 O. Urinary Bladder & Prostate Metaplastic Carcinoma vs Inflammatory Pseudotumor Prostatic Adenocarcinoma vs Urothelial Carcinoma Adenocarcinoma vs Glandular Hyperplasia Prostatic Adenocarcinoma vs Adenocarcinoma of Colon 250 P. Testis Seminoma vs Embryonal Carcinoma 252 Q. Skin Paget Disease vs Bowen Disease Paget Disease vs In Situ Melanoma Bowen Disease vs In Situ Melanoma Merkel Cell Carcinoma vs Basal Cell Carcinoma Merkel Cell Carcinoma vs Small Cell Lung Carcinoma Sebaceous Carcinoma vs Squamous Cell Carcinoma Desmoplastic Melanoma vs Dermal Fibrous Scar Dermatofibroma vs Dermatofibrosarcoma Kaposi Sarcoma vs Leiomyosarcoma Epithelioid Angiosarcoma vs Poorly Differentiated Carcinoma Granular Cell Tumor vs Histiocytic Skin Reaction Glomus Tumor vs Morphologically Similar Lesions Myeloid Leukemic Infiltrate vs Malignant Lymphoma Mast Cell Disease vs Other Cell Infiltrates Metastatic Carcinoma in the Skin 296 a. Metastatic Carcinoma of Thyroid 297 b. Metastatic Carcinoma of Breast 299 c. Metastatic Renal Cell Carcinoma 301 R. Central Nervous System Meningioma vs Schwannoma High Grade Glioma vs Metastatic Carcinoma High Grade Glioma vs Metastatic Melanoma 308 References 310 Index 313 vii
8 Preface Close to a quarter of a century ago, we wrote a monograph titled Immunoperoxidase Techniques: A Practical Approach to Tumor Diagnosis, and stated at that time that the practice of pathology has been changed by immunohistochemistry. The writing of that monograph was prompted by the assertion that the lack of a practical manual on the subject prevented pathologists from gaining full benefits of the technique in the daily assessment of surgical tissue samples. Today, immunohistochemistry is an integral part of the daily practice of pathology and there is hardly a day that goes by without the discovery of a new tumor marker. Nor is there a single issue of pathology or other specialty journals that fails to carry an article or a direct reference to immunohistochemistry. In fact, during the last 25 years, more than 165,000 articles and many textbooks have been published on that subject. Consequently, pathologists are challenged to convert the benefits from the florid array of new developments and informations in the field into the daily practice of surgical pathology. As was the case with the original monograph, our intent is to facilitate that task. Therefore, this can be considered as an update on the observations that we have made in the course of the past 25 years by adhering to practicality as the single most important criterion in the resolution of daily diagnostic problems encountered by surgical pathologists. Whenever appropriate, this approach can be complemented by referring to more exhaustive treatises such as Taylor, Clive R and Cote, Richard J, Immunomicroscopy A Diagnostic Tool for the Surgical Pathologist; and Dabbs, David J, Diagnostic Immunohistochemistry. Updates on tumor markers may be obtained by visiting the ImmunoQuery Web site, Frisman, Dennis M., viii
9 Acknowledgments This manual reflects the application of immunohistochemistry in the resolution of differential diagnostic problems encountered daily in the practice of surgical pathology at the University of Miami Jackson Memorial Hospital and Sylvester Comprehensive Cancer Center. Our practice encompasses cases originated from these institutions as well as those that are referred from colleagues in the United States, primarily from Florida, and also from outside the United States. We therefore acknowledge the benefits derived from more than two decades of interaction with the faculty in our department and our peers in Florida and elsewhere. We have been most fortunate in maintaining a dedicated, responsible and most competent technical staff in our immunohistochemistry laboratory. Silvia Losa, Blanca Cuenca, Weiyu Wu, and Fay Mucha have provided their skills and commitment to the well being of our patients and to the success of our research endeavors throughout these years. We would like to extend a very special note of gratitude to Alicia Cabrera who confronted the demands of writing and many times revising the manuscript with forbearance, professionalism, and gracious attitude. The extended efforts of Drs. Parvin Ganjei, Betina Werner and Rima Kanhoush in the preparation of this manual were essential for bringing it about. To Joshua Weikersheimer of the ASCP Press, we owe special thanks for his advice and continuous support. We also like to thank Doug Sweet, Vice President, Celerus Diagnostics, who was instrumental in encouraging us to undertake this project. ix
10 Introduction Immunohistochemistry is now an integral part of every diagnostic pathology laboratory. Its major application is to complement histomorphology in classification of human neoplasms. With the refinement of methodologies, the availability of good quality reagents, and enhancement of the reproducibility of results by introduction of automatic stainers, problems associated with the technical aspects of immunohistochemistry are relatively uncommon. Current limitations of efficient application of immunohistochemistry in diagnostic pathology are mostly analytical, usually related to selection of appropriate markers for a diagnostic problem, as well as the correct interpretation of staining result and its incorporation in the final diagnostic decision. Factors that influence the analytical outcome include scarcity of cell lineage-specific markers, subjectivity of panel selection, lack of practical guidelines, and the experience of the observer. It is not surprising, therefore, to witness the drastic increase in the number of antibodies used in immunohistochemical panels. However, the indiscriminate use of multiple antibodies without consideration of histomorphology and clinical history the shotgun approach is neither diagnostically efficient, nor cost-effective. Often, it entangles the pathologists in a confusing web of positive and negative staining results, leading to indeterminate or incorrect diagnostic conclusions. In practice, however, based on histologic appearance of the tumors, most differential diagnoses in tissue biopsies can be narrowed down to two or three possibilities. Consequently, the choice of antibodies in these situations can also be restricted to two or three. In this practical handbook we recommend simple guidelines for the resolution of most common and some uncommon diagnostic problems by utilization of a limited number of antibodies. This is not an algorithm; it is a tailor-made approach that requires the pathologist s input and necessitates his/her active participation by formulating a working differential diagnosis on the basis of clinical information and histomorphology. Before using the book: 1. The suggested markers are those that we have found most useful. The experienced immunohistochemist may like to use the same set of markers or modify the selection according to his/her preference. The user will find that some of the most commonly utilized immunohistochemical markers are conspicuously absent. We have omitted those we have found to be of limited or no value in a given differential diagnosis, even when they are used in a panel. 2. Not all possible differential diagnostic problems are discussed. This is primarily due to the lack of reliable markers for some common differential diagnoses. For example, there are at least a dozen publications on immunohistochemical separation of renal oncocytomas from chromophobe renal cell carcinomas. None of the several different purported markers in these papers, however, has proved to be useful, at least in our experience. 3. The illustrated images are from cases seen in our own institution or referrals from colleagues in Florida and elsewhere. We have made no attempt to present the most typical examples of each diagnostic entity or the best possible histologic preparations. On the contrary, the majority of illustrations are from cases that may show crushing artifacts, knife nicks, thermal damage, or other changes that most pathologists are familiar with in their daily practice. 4. Some images exhibit positive staining as dark brown, or black, on a green background. This is notable for nuclear antigens because we intensify the color of DAB with a dip in copper sulphate and use fast green as a cytoplasmic counterstain. 5. Finally, we have only discussed and illustrated the immunohistochemistry of human solid tumors. The IHC of hematolymphoid neoplasms is not addressed except when they come into the differential diagnosis of a non-lymphoid neoplasm. The IHC of hematolymphoid neoplasms is a rather vast area and is beyond the scope of this publication.. x
Index. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, 272-275 5-HT, see Serotonin
A Acantholytic squamous cell carcinoma vs epithelioid angiosarcoma, 56-57 Acinic cell carcinoma of pancreas, 76-77 vs ductal adenocarcinoma, 74-75 vs islet cell tumor, 78-81 Adenomatoid tumor vs hemangioma,
MODERN IMMUNOHISTOCHEMISTRY
MODERN IMMUNOHISTOCHEMISTRY Cambridge Illustrated Surgical Pathology Peiguo G. Chu City of Hope National Medical Center, Duarte, California Lawrence M. Weiss City of Hope National Medical Center, Duarte,
Contents. 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1. 2. Head, Neck, Orbit and Salivary Glands... 12
Contents 1. Introduction and Approach to Fine Needle Aspiration Cytology... 1 Complications 1 Fine Needle Aspiration Technique 1 Evaluation of FNAC Smear 4 Cell Morphology 4 Nucleus 4 Cytoplasm 6 Background
Immunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
Update on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
4/15/2013. bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o. anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma
Chapter Sixteen Oncology bi/o carcin/ chem/o immun/o onc/o radi/o sarc/o Combining Forms Prefixes and Suffixes Carcinogenesis anabrachydysectoendoneo- -ectomy -genesis -oma -plasia -sarcoma Causes of cancer
Practical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
Seattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
Immunohistochemistry of soft tissue tumors
Immunohistochemistry of soft tissue tumors Immunohistochemistry Major advances : antigen retrieval techniques (HIER) sensitive detection systems numerous antibodies of good quality Standardization : automated
Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.
Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic
Outline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
The develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
Pathology of lung cancer
Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu
Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
Diagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 [email protected]
Frozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
PROTOCOL OF THE RITA DATA QUALITY STUDY
PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of
Chapter I Overview Chapter Contents
Chapter I Overview Chapter Contents Table Number Contents I-1 Estimated New Cancer Cases and Deaths for 2005 I-2 53-Year Trends in US Cancer Death Rates I-3 Summary of Changes in Cancer Incidence and Mortality
The Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD
TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD Victor E. Reuter, MD Memorial Sloan-Kettering Cancer Center [email protected] 66 th Annual Pathology Seminar California Society of Pathologists Short
Immunohistochemistry in the Diagnosis of Metastatic Carcinoma of Unknown Primary Origin
Immunohistochemistry in the Diagnosis of Metastatic Carcinoma of Unknown Primary Origin Rodney T. Miller, M.D. Director of Immunohistochemistry ProPath Laboratory 1355 River Bend Drive Dallas, TX 75247-4915
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
This module consists of four units which will provide the user a basic knowledge of cancer as a disease.
Module 5: What is Cancer? This module consists of four units which will provide the user a basic knowledge of cancer as a disease. After completing this module, cancer abstractors will be able to: Define
Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules
Multiple Primary and Histology Site Specific Coding Rules KIDNEY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology
The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
Thyroid Transcription Factor-1 (TTF 1): protein expression is not exclusive to lung and thyroid tissue.
Thyroid Transcription Factor-1 (TTF 1): protein expression is not exclusive to lung and thyroid tissue. Scorer PW, Pinkney M, McIntosh GG. Leica Biosystems Newcastle Ltd, Balliol Business Park West, Benton
DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE
DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE Ryan Granger University of Rhode Island Cytotechnology program May 2, 2015 ASCT Annual Meeting Nashville, Tennessee DESMOPLASTIC SMALL ROUND
Oncology. Topic-Bile Duct Carcinoma. Topic-Adenocarcinoma, Lung. Topic-Hemangiosarcoma, Spleen and Liver
Topic-Adenocarcinoma, Lung Figure 1. Pulmonary adenocarcinoma. Figure 2. Pulmonary bronchiolar carcinoma. Figure 3. Pulmonary fibrosarcoma. Topic-Adenocarcinoma, Skin (Sweat Gland, Sebaceous) Figure 1.
Cytopathology Case Presentation #8
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
A 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
Rare Thoracic Tumours
Rare Thoracic Tumours 1. Epithelial Tumour of Trachea 1 1.1 General Results Table 1. Epithelial Tumours of Trachea: Incidence, Trends, Survival Flemish Region 2001-2010 Both Sexes Incidence Trend EAPC
BIOBANK LPCE-NICE CHEST
BIOBANK LE-NIE HEST athologist :. BUTORI 12/09/2013 LE / HU Unit atient : N LH13-3603 N LB 13-0691 ID : RO A onsent : YES Age : 54 Diagnosis and staging : chronic pleuresia 5x1000µL BIOBANK LE-NIE HEST
Common Cancers & Hereditary Syndromes
Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.
Something Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
Report series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
The Ontario Cancer Registry moves to the 21 st Century
The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer
Notice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada [email protected] Notice of Faculty Disclosure In accordance with
FRCPath Part 2 Histopathology Short Cases, autumn 2014
FRCPath Part 2 Histopathology Short Cases, autumn 2014 Commentary Case 1 Female age 52: palpable lesion, left breast Breast, fat necrosis. Average: 2.6/5 This case was chosen as a good example of fat necrosis
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow ([email protected]) Uma R Chandran ([email protected])
BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner
BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome Thomas Wiesner Disclosure Listed as co-inventor US patent application US 61/463,389 BAP1 mutational analysis in determining susceptibility
Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!
Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor of
History. Female age 64. Tumour right kidney on scan. Partial nephrectomy. Tumour 18mm diameter.
FRCPath Part 2 Histopathology Examination Histology short cases Commentary. Case 1. History. Female age 64. Tumour right kidney on scan. Partial nephrectomy. Tumour 18mm diameter. Diagnosis: Angiomyolipoma
C a nc e r C e nter. Annual Registry Report
C a nc e r C e nter Annual Registry Report 214 214 Cancer Registry Report Larraine A. Tooker, CTR Please note that the 214 Cancer Registry Annual Report is created in 214, but it reflects data on cases
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM. ChromoPlex 1 Dual Detection for BOND
ChromoPlex 1 Dual Detection for BOND FULLY AUTOMATED PARALLEL DUAL STAINING DETECTION SYSTEM View multiple antibodies on a single slide to deliver a comprehensive clinical result. 1 MULTIPLY YOUR CAPABILITIES
Immunohistochemistry on cytology specimens from pleural and peritoneal fluid
Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Dr Naveena Singh Consultant Pathologist Bart health NHS Trust London United Kingdom Disclosures and Acknowledgements I have
How To Test For Cancer
Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland Diagnostic
page antibody Adipophilin (polyclonal) ALDH1A1 (44) c-myc (EP121) * Cadherin-17 (SP183) Cathepsin K (3F9)
New IHC Antibodies 2 Table of Contents page antibody 1 2 3 4 5 6 7 8 Adipophilin (polyclonal) ALDH1A1 (44) c-myc (EP121) * Cadherin-17 (SP183) Cathepsin K (3F9) Caveolin-1 (2297) CD13 (SP187) CD16 (SP175)
Pediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
New Hampshire Childhood Cancer
Introduction: New Hampshire Childhood Cancer New Hampshire, Childhood Cancer, January 2009 Issue Brief Cancer in children is relatively uncommon, impacting fewer than twenty two of every 100,000 children
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 BEFORE: M. Crystal: Vice-Chair HEARING: August 20, 2014 at Toronto Written DATE OF DECISION: December 4, 2014 NEUTRAL CITATION: 2014
THE PATHOLOGY OF MEDIASTINAL MASSES. Anatomic Distribution of Mediastinal Masses
Page 1 of 5 THE PATHOLOGY OF MEDIASTINAL MASSES Dr. S. Boag 549-6666 Ext. 4190, mailto:%[email protected] 1. INTRODUCTION A wide range of process, neoplastic and non-neoplastic, can produce
CHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
Renal Pathology Update. Sundus Hussein MD, FRCPC
Renal Pathology Update Sundus Hussein MD, FRCPC Case History A 45 year old male with incidentally discovered a 3.5 x 3.9 x 2.7 cm renal mass Handling partial nephrectomy Handling partial nephrectomy
Diagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
The term undifferentiated tumor has been used in reference
Undifferentiated Tumor True Identity by Immunohistochemistry Armita Bahrami, MD; Luan D. Truong, MD; Jae Y. Ro, MD, PhD Context. Undifferentiated tumor refers to a heterogeneous group of neoplasms with
Effusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
YOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
THE CANCER CENTER 2013 ANNUAL REPORT CONTAINING 2012 STATISTICS
THE CANCER CENTER 2013 ANNUAL REPORT CONTAINING 2012 STATISTICS Northside Medical Center Cancer Committee Mission Statement It is the mission of the Cancer Committee to evaluate and monitor the care of
CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY
CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY CASE HISTORY 52Y MALE RIGHT RADICAL NEPHERECTOMY Case of right renal mass with IVC thrombus. History of surgery and RT for right occipital
How To Test For Cancer With A Blood Test
Histolab Products AB Eva Alströmer Jonas Falgén Helsingborg 7-8/10 2010 Table 1 Formalin Fixation Times and Estrogen Receptor Staining With 25 Minutes Antigen Retrieval Pretreatment Formalin Q-Score Difference
ISOLATED PANCREATIC METASTASIS OF A MALIGNANT PLEURAL MESOTHELIOMA
ISOLATED PANCREATIC METASTASIS OF A MALIGNANT PLEURAL MESOTHELIOMA Yi-Ting Lin, 1 Bing-Shiun Wu, 2 Sheau-Fang Yang, 3 and Huang-Chi Chen 4 Departments of 1 Family Medicine, 2 Internal Medicine, and 3 Pathology,
Ovarian tumors Ancillary methods
Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of
Number. Source: Vital Records, M CDPH
Epidemiology of Cancer in Department of Public Health Revised April 212 Introduction The general public is very concerned about cancer in the community. Many residents believe that cancer rates are high
Lung Cancer. Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine
Lung Cancer Ossama Tawfik, MD, PhD Professor, Vice Chairman Director of Anatomic &Surgical Pathology University of Kansas School of Medicine Alexandria, Egypt July 1-1 3, 2008 OBJECTIVES Describe and
NEOPLASMS C00 D49. Presented by Jan Halloran CCS
NEOPLASMS C00 D49 Presented by Jan Halloran CCS 1 INTRODUCTION A neoplasm is a new or abnormal growth. In the ICD-10-CM classification system, neoplastic disease is classified in categories C00 through
INDEX. Performance Improvement Program in Surgical Pathology SURVEYS 2012 AND ANATOMIC PATHOLOGY EDUCATION PROGRAMS
INDEX SURVEYS 2012 AND ANATOMIC PATHOLOGY EDUCATION PROGRAMS Performance Improvement Program in Surgical Pathology PIP CASE SUMMARY INDEX 1989-2012 Breast 89-17 Angiosarcoma 86% 89-37 Tubular adenoma 97%
HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: [email protected] 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from
The WHO Classification of Renal Tumors and Common Issues in TNM Staging for Renal Cell Carcinoma
The WHO Classification of Renal Tumors and Common Issues in TNM Staging for Renal Cell Carcinoma Steven Shen, M.D.,Ph.D. Staff Pathologist and Assistant Member The Methodsit Hospital and Research Institute
Grossing & Intraoperative Evaluation Boot Camp
AP RTC July 2011 Moffitt: HSW- 532 Zion: B2 Conf. Room MON TUES WED THURS FRI Grossing & Intraoperative Evaluation Boot Camp 4 5 6 Lymph node & general principles in gross pathology - Grossing principles
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin)
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin) Product Code: NCL-L-CD141 Leica Biosystems Newcastle Ltd Balliol Business Park West Benton Lane Newcastle Upon Tyne NE12 8EW United Kingdom
CARDCARE PROTECTOR CERTIFICATE OF INSURANCE
CARDCARE PROTECTOR CERTIFICATE OF INSURANCE DBS Bank Ltd ( DBS ) is the master policyholder under Group Policy No. MD00000002 (the Policy ), underwritten by Manulife (Singapore) Pte. Ltd. (the Insurer
OBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
Immunohistochemistry of clear cell tumours. What are clear cell tumours? Jan Klos 1
Immunohistochemistry of clear cell tumours J. Klos MD Department of Pathology Stavanger University Hospital Norway What are clear cell tumours? Multiple factors in etiology of clear cell changes: - technical
Ep-CAM/Epithelial Specific Antigen (MOC-31)
Ep-CAM/Epithelial Specific Antigen (MOC- Product Identification Cat. No. Description 44588 EP-CAM 0,1 M (MOC- 44589 EP-CAM 1 M (MOC- 44283 EP-CAM RTU M (MOC- Symbol Definitions P C A E S DIL DOC# DIS ready-to-use
Histopathology of Major Salivary Gland Neoplasms
Histopathology of Major Salivary Gland Neoplasms Sam J. Cunningham, MD, PhD Faculty Advisor: Shawn D. Newlands, MD, PhD Faculty Advisor: David C. Teller, MD The University of Texas Medical Branch, Department
Case of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.
Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging system
A. Pericardial smear. Examination of the pericardial aspirate can provide useful diagnostic information.
5. PERICARDIUM Heart is encased by the pericardium which has a visceral layer (a) covering the heart and the parietal layer (b). In normal states it is thin, transparent and the myocardium can be seen
Multiple Primary and Histology Coding Rules
Multiple Primary and Histology Coding Rules January 10, 2008 National Cancer Institute Surveillance Epidemiology and End Results Program Bethesda, MD PLEASE NOTE This PDF of the 2007 Multiple Primaries
3-F. Pathology of Mesothelioma
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which
Immunohistochemistry in diagnostic pathology of tumors. Approach, benefits, limits and pitfalls
Aus dem Institut für Pathologie der Medizinischen Fakultät Charité Universitätsmedizin Berlin DISSERTATION Immunohistochemistry in diagnostic pathology of tumors. Approach, benefits, limits and pitfalls
190.25 - Alpha-fetoprotein
Other Names/Abbreviations AFP 190.25 - Alpha-fetoprotein Alpha-fetoprotein (AFP) is a polysaccharide found in some carcinomas. It is effective as a biochemical marker for monitoring the response of certain
Emerging Subtypes in Renal Cancer. Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology dhansel@ucsd.
Emerging Subtypes in Renal Cancer Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology [email protected] Some General Comments Fuhrman nuclear grading clear cell
FNA Cytology of Mediastinal Lesions. Presenters: Xiaoqi Lin, M.D., Ph.D. Ritu Nayar, M.D.
Disclosure information The speakers have no relationship that represents a possible conflict of interest with respect to the content of this presentation. FNA Cytology of Mediastinal Lesions Presenters:
